09-27-04

IFW



EXPRESS MAIL NO. EV449562501US

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/685,305
Filing Date	October 14, 2003
First Named Inventor	Orest W. Blaschuk
Art Unit	1637
Examiner Name	
Attorney Docket No.	100086.411C2

ENCLOSURES (*check all that apply*)

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement; Form PTO-1449 (3 Sheets)
- ☒ 25 Cited References
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts under 37 C.F.R. 1.52 or 1.53
- ☐ Response to Missing Parts/Incomplete Application
- ☐ Drawing(s)
- ☐ Request for Corrected Filing Receipt
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation, Change of Correspondence Address
- ☐ Declaration
- ☐ Statement under 37 CFR 3.73(b)
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD(s), Number of CD(s) _____
- ☐ After Allowance Communication to Technology Center (TC)
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Return Receipt Postcard
- ☐ Additional Enclosure(s) *(please identify below)*:

_____
_____
_____
_____

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey E. Hundley, Ph.D., Patent Agent Reg. No. 42,676	Customer Number 00500
Signature		
Date	September 16, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

VIA EXPRESS MAIL

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

\511504

OIPE JC60 SEP 16 2004 PATENT & TRADEMARK OFFICE

EXPRESS MAIL NO. EV449562501US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Orest W. Blaschuk et al.
Application No.	:	10/685,305
Filed	:	October 14, 2003
For	:	COMPOUNDS AND METHODS FOR MODULATING BETA-CATENIN MEDIATED GENE EXPRESSION

Art Unit	:	1637
Docket No.	:	100086.411C2
Date	:	September 16, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jeffrey E. Hundley, Ph.D., Patent Agent
Registration No. 42,676

JEH:ljt

Enclosures:

Postcard
Transmittal Form
Form PTO-1449 (3 Sheets)
Cited References (25)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\511506

EXPRESS MAIL NO. EV449562501US

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	APPLICATION NO.
		100086.411C2	10/685,305
		APPLICANTS	
		Orest W. Blaschuk et al.	
		FILING DATE	GROUP ART UNIT
		October 14, 2003	1637

SEP 16 2004 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,652,122	07/29/97	Frankel et al.	435	69.7	
	AB	5,719,130	02/17/98	Takeuchi et al.	514	34	
	AC	5,723,578	03/03/98	Coy et al.	530	326	
	AD	6,031,072	02/29/00	Blaschuk et al.	530	317	
	AE	6,303,576	10/16/01	Blaschuk et al.	514	14	
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	AJ	CA 2357015 A1	8/26/99	Canada		
	AK	WO 98/42296	10/01/98	WIPO		
	AL	WO 98/45319	10/15/98	WIPO		
	AM	WO 98/49561	11/05/98	WIPO		
	AN	WO 99/00138	01/07/99	WIPO		
	AO	WO 99/42481	08/26/99	WIPO		

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AP		Aberle et al., "β-catenin is a target for the ubiquitin-proteasome pathway," *The EMBO Journal 16*(13):3797-3804, 1997.
	AQ		Barker and Clevers, "Catenins, Wnt signaling and cancer," *Bioessays 22*(11):961-965, October 2000.
	AR		Butz et al., "Plakoglobin and β-Catenin: Distinct But Closely Related," *Science 257*:1142-1144, Aug. 1992.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	APPLICATION NO.
		100086.411C2	10/685,305
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS: Orest W. Blaschuk et al.	
		FILING DATE: October 14, 2003	GROUP ART UNIT: 1637

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	BB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	BC		Easwaran et al., "The Ubiquitin/Proteosome Pathway And Apc Regulation of Beta-Catenin/Lef Signaling," *Mol. Biol. Cell 9*:248a, Abstract No. 1440, November 1998.
	BD		Gat et al., "De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin," *Cell 95*:605-614, Nov. 1998.
	BE		He et al., "Identification of c-MYC as a Target of the APC Pathway," *Science 281*:1509-1512, Sep. 1998.
	BF		Heery et al., "A signature motif in transcriptional co-activators mediates binding to nuclear receptors," *Nature 387*:733-736, Jun. 1997.
	BG		Hülsken et al., "E-Cadherin and APC Compete for the Interaction with β-Catenin and the Cytoskeleton," *J. Cell Biology 127* (6):2061-2069, Dec. 1994.
	BH		Huelsken et al., "E-Cadherin and APC Compete for the Interaction with β-Catenin and the Cytoskeleton," EMBL Sequence Database, Accession No. A38973, Jan. 1996.
	BI		Huelsken et al., "E-Cadherin and APC Compete for the Interaction with β-Catenin and the Cytoskeleton,"EMBL Sequence Database, Accession No. P35222, Feb. 1994.
	BJ		Morin, "β-catenin signaling and cancer," *Bioessays 21*(21):1021-1030, Dec. 1999.
	BK		Novak and Dedhar, "Signaling through β-catenin and Lef/Tcf," Cellular and Molecular *Life Sciences 56*(5-6):523-537, Oct. 30, 1999.
	BL		Orford et al., "Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin," *The Journal of Biological Chemistry 272*(40):24735-24738, October 1997.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.411C2	APPLICATION NO. 10/685,305
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE October 14, 2003	GROUP ART UNIT 1637

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	CB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	CC		Oro and Scott, "Splitting Hairs: Dissecting Roles of Signaling Systems in Epidermal Development," *Cell 95*:575-578, November 1998.
	CD		Polakis, "The oncogenic activation of β-catenin," *Current Opinion in Genetics & Development 9*(1):15-21, Feb. 1999.
	CE		Salomon et al., "Regulation of β-Catenin Levels and Localization by Overexpression of Plakoglobin and Inhibition of the Ubiquitin-Proteasome System," *The Journal of Cell Biology 139*(5):1325-1335, December 1997.
	CF		Torchia et al., "The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function," *Nature 387*:677-684, June 1997.
	CG		Willert and Nusse, "β-catenin: a key mediator of Wnt signaling," *Current Opinion in Genetics and Development 8*:95-102, 1998.
	CH		Zhang et al., "Destabilization of β-Catenin by mutations in presenilin-1 potentiates neuronal apoptosis," *Nature 395*:698-702, Oct. 1998.
	CI		
	CJ		
	CK		
	CL		

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).